Reveals increased mortality with adaptive servo-ventilation in systolic heart failure and central sleep apnea, indicating potential harm from this therapy.
Adaptive servo-ventilation had no significant effect on the primary end point in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality were both increased with this therapy. (Funded by ResMed and others; SERVE-HF ClinicalTrials.gov number, NCT00733343.).
No takes yet. Share an insight, caveat, or question.
Cowie et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: